A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients

NCT02415985 Phase 2 COMPLETED

To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients

Details

Lead sponsor	The HIV Netherlands Australia Thailand Research Collaboration
Phase	Phase 2
Status	COMPLETED
Enrolment	40
Start date	2015-06
Completion	2019-12

Conditions

• HIV
• Tuberculosis

Interventions

• Lopinavir/r will be supplied by NHSO/GPO
• Rifabutin

Primary outcomes

• pharmacokinetics of rifabutin Cmax — 48 weeks
  Cmax The peak plasma concentration of rifabutin after administration

Countries

Thailand